In Section C, individuals will acquire ABBV-744 and oral navitoclax. In Segment D, individuals will receive ABBV-744 and ruxolitinib. Participants will get treatment right until condition progression or perhaps the members are not able to tolerate the study drugs. There might be bigger treatment stress for contributors Within this trial https://williamt999fqb1.izrablog.com/profile